1 results

The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients with Systemic Lupus Erythematosus
People with systemic lupus erythematosus (SLE) are at risk of developing complications in their blood vessels. The risks increase for heart attacks or stroke. No medications have been effective at reducing this risk in people with lupus. Researchers at NIH are testing whether a drug (anifrolumab) can improve blood vessel function and reduce blood vessel inflammation in people with (SLE). Participants do not pay for tests, treatments, or procedures.
Learn More